Lin28 regulates HER2 and promotes malignancy through multiple mechanisms

Cell Cycle

Volumn 11, Issue 13, 2012, Pages 2486-2494

  Feng, Chen ^a,c   Neumeister, Veronique ^a   Ma, Wei ^a,d   Xu, Jie ^a   Lu, Lingeng ^b   Bordeaux, Jennifer ^a   Maihle, Nita J ^a   Rimm, David L ^a   Huang, Yingqun ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY   (China)

^d NORTH MINZU UNIVERSITY   (China)

Author keywords

Breast cancer; Her2 (ErbB2 neu); Lin28; Post transcriptional

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PROTEIN LIN28; PROTEIN TYROSINE KINASE; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PLEIOTROPY; PREDICTOR VARIABLE; PROTEIN EXPRESSION;

EID: 84863808561     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20893     Document Type: Article

References (45)

1. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009; 41:843-8; PMID:19483683; http://dx.doi.org/10. 1038/ng.392.
2. Zhu H, Shah S, Shyh-Chang N, Shinoda G, Einhorn WS, Viswanathan SR, et al. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet 2010; 42:626-30; PMID:20512147; http://dx.doi.org/10.1038/ng.593.
3. Yang DH, Moss EG. Temporally regulated expression of Lin-28 in diverse tissues of the developing mouse. Gene Expr Patterns 2003; 3:719-26; PMID:14643679; http://dx.doi.org/10.1016/S1567-133X(03)00140-6.
4. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol 2008; 18:505-16; PMID:18774294; http://dx.doi.org/10.1016/j.tcb.2008.07.007.
5. Huang Y. A mirror of two faces: Lin28 as a master regulator of both miRNA and mRNA. Wiley Interdiscip Rev RNA 2012.
6. Peng S, Chen LL, Lei XX, Yang L, Lin H, Carmichael GG, et al. Genome-wide studies reveal that Lin28 enhances the translation of genes important for growth and survival of human embryonic stem cells. Stem Cells 2011; 29:496-504; PMID:21425412; http://dx.doi.org/10.1002/stem.591.
7. Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS, et al.; DIAGRAM Consortium; MAGIC Investigators. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011; 147:81-94; PMID:21962509; http://dx.doi.org/10. 1016/j.cell.2011.08.033.
8. Guo Y, Chen Y, Ito H, Watanabe A, Ge X, Kodama T, et al. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene 2006; 384:51-61; PMID:16971064; http://dx.doi.org/10.1016/j. gene.2006.07.011.
9. Wang YC, Chen YL, Yuan RH, Pan HW, Yang WC, Hsu HC, et al. Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis 2010; 31:1516-22; PMID:20525879; http://dx.doi.org/10. 1093/carcin/bgq107.
10. Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, et al. MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 2010; 52:1731-40; PMID:20827722; http://dx.doi.org/10.1002/hep.23904.
11. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 2010; 70:9463-72; PMID:21045151; http://dx.doi.org/10.1158/0008-5472.CAN-10-2388.
12. King CE, Wang L, Winograd R, Madison BB, Mongroo PS, Johnstone CN, et al. LIN28B fosters colon cancer migration, invasion and transformation through let- 7-dependent and -independent mechanisms. Oncogene 2011; 30:4185-93; PMID:21625210; http://dx.doi.org/10.1038/onc.2011.131.
13. King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, Rustgi AK. LIN28B promotes colon cancer progression and metastasis. Cancer Res 2011; 71:4260-8; PMID:21512136; http://dx.doi.org/10.1158/0008-5472.CAN-10-4637.
14. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 2010; 29:2153-9; PMID:20101213; http://dx.doi.org/10.1038/onc.2009.500.
15. Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, et al. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. Eur J Cancer 2009; 45:2212-8; PMID:19477633; http://dx.doi.org/10.1016/ j.ejca.2009.05.003.
16. West JA, Viswanathan SR, Yabuuchi A, Cunniff K, Takeuchi A, Park IH, et al. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 2009; 460:909-13; PMID:19578360.
17. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NFkappaB, Lin28, Let-7 MicroRNA and IL6 links inflammation to cell transformation. Cell 2009; 139:693-706; PMID:19878981; http://dx.doi.org/10. 1016/j.cell.2009.10.014.
18. Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J 2009; 28:347-58; PMID:19153603; http://dx.doi.org/10.1038/emboj.2008.294.
19. Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 2011; 147:1066-79; PMID:22118463; http://dx.doi.org/10.1016/j. cell.2011.10.039.
20. Viswanathan SR, Daley GQ. Lin28: A microRNA regulator with a macro role. Cell 2010; 140:445-9; PMID:20178735; http://dx.doi.org/10.1016/j.cell.2010.02. 007.
21. Nam Y, Chen C, Gregory RI, Chou JJ, Sliz P. Molecular basis for interaction of let-7 microRNAs with Lin28. Cell 2011; 147:1080-91; PMID:22078496; http://dx.doi.org/10.1016/j.cell.2011.10.020.
22. Newman MA, Hammond SM. Emerging paradigms of regulated microRNA processing. Genes Dev 2010; 24:1086-92; PMID:20516194; http://dx.doi.org/10. 1101/gad.1919710.
23. Lehrbach NJ, Miska EA. Regulation of pre-miRNA Processing. Adv Exp Med Biol 2010; 700:67-75; http://dx.doi.org/10.1007/978-1-4419-7823-3-7.
24. Balzer E, Heine C, Jiang Q, Lee VM, Moss EG. LIN28 alters cell fate succession and acts independently of the let-7 microRNA during neurogliogenesis in vitro. Development 2010; 137:891-900; PMID:20179095; http://dx.doi.org/10. 1242/dev.042895.
25. Vadla B, Kemper K, Alaimo J, Heine C, Moss EG. lin-28 controls the succession of cell fate choices via two distinct activities. PLoS Genet 2012; 8:1002588; PMID:22457637; http://dx.doi.org/10.1371/journal.pgen.1002588.
26. Jin J, Jing W, Lei XX, Feng C, Peng S, Boris-Lawrie K, et al. Evidence that Lin28 stimulates translation by recruiting RNA helicase A to polysomes. Nucleic Acids Res 2011; 39:3724-34; PMID:21247876; http://dx.doi.org/10.1093/ nar/gkq1350.
27. Qiu C, Ma Y, Wang J, Peng S, Huang Y. Lin28-mediated post-transcriptional regulation of Oct4 expression in human embryonic stem cells. Nucleic Acids Res 2010; 38:1240-8; PMID:19966271; http://dx.doi.org/10.1093/nar/gkp1071.
28. Lei XX, Xu J, Ma W, Qiao C, Newman MA, Hammond SM, et al. Determinants of mRNA recognition and translation regulation by Lin28. Nucleic Acids Res 2012; 40:3574-84; PMID:22210884; http://dx.doi.org/10.1093/nar/gkr1279.
29. Wilken JA, Maihle NJ. Primary trastuzumab resistance: new tricks for an old drug. Ann NY Acad Sci 2010; 1210:53-65; PMID:20973799; http://dx.doi.org/10. 1111/j.1749-6632.2010.05782.x.
30. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61:1-13; PMID:11694782; http://dx.doi.org/10.1159/000055396.
31. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244:707-12; PMID:2470152; http://dx.doi.org/10.1126/Science. 2470152.
32. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97; PMID:20728210; http://dx.doi.org/10. 1016/S0140-6736(10)61121-X.
33. Moeder CB, Giltnane JM, Moulis SP, Rimm DL. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol 2009; 520:163-75; PMID:19381954; http://dx.doi.org/10.1007/978-1-60327-811-9-12.
34. Sakurai M, Miki Y, Masuda M, Hata S, Shibahara Y, Hirakawa H, et al. LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. J Steroid Biochem Mol Biol 2011; PMID:22081076; http://dx.doi.org/10.1016/j.jsbmb.2011.10.007.
35. Lordick F. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 2011; 7:187-99; PMID:21345138; http://dx.doi.org/10.2217/fon.10.178.
36. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40:56-63; PMID:14687790; http://dx.doi.org/10.1016/j.ejca.2003.08.027.
37. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 2005; 124:273-81; PMID:16040300; http://dx.doi.org/10.1309/J9VXABUGKC4Y07DL.
38. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs. resection specimens for equivocal (immunohistochemical score 2+) cases. Mod Pathol 2008; 21:363-8; PMID:18246053; http://dx.doi.org/10.1038/ modpathol.3801021.
39. Yang YL, Fan Y, Lang RG, Gu F, Ren MJ, Zhang XM, et al. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance. Breast Cancer Res Treat 2012; PMID:22476857; http://dx.doi.org/10.1007/s10549-012-2046-0.
40. Fedele M, Fusco A. HMGA and cancer. Biochim Biophys Acta 2010; 1799:48-54; PMID:20123067.
41. Palmieri D, Valentino T, D'Angelo D, De Martino I, Postiglione I, Pacelli R, et al. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene 2011; 30:3024-35; PMID:21339738; http://dx.doi.org/10.1038/onc.2011.21.
42. Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 2010; 8:1000563; PMID:21203579; http://dx.doi.org/10.1371/journal.pbio.1000563.
43. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17:461-9; PMID:21399647; http://dx.doi.org/ 10.1038/nm.2309.
44. Allison M. The HER2 testing conundrum. Nat Biotechnol 2010; 28:117-9; PMID:20139941; http://dx.doi.org/10.1038/nbt0210-117.
45. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003; 63:1445-8; PMID:12670887.